Abstract 3430
Background
Immune checkpoint inhibition monotherapy has shown no efficacy in microsatellite-stable (MSS) CRC. Combination strategies are being studied to increase the immunogenicity of this cold tumor. Humanized mice are promising models to evaluate immunotherapy combinations and their effects in the engrafted human immune system.
Methods
3 MSS CRC patient-derived xenografts were injected subcutaneously into 68 mice previously humanized through CD34+ cord blood-derived hematopoietic cell transplantation. Mice were allocated into 4 equivalent groups based on human chimerism detected in the blood and subsequently treated with anti-PD-1 therapy and/or multi-tyrosine kinase inhibition. At harvest, flow cytometry immune data from the lymph nodes (LN), the spleen (SP) and tumor-infiltrating lymphocytes (TIL) were analyzed. Mice were classified according to the specific growth rate (SGR, % volume / day) of their tumor/s into R (under median SGR) vs non-R (over median SGR).
Results
50 mice were considered either R (26) or non-R (24). In the peripheral immune organs (LN and SP), the total number of immune cells was similar between R and non-R mice. However, a higher percentage of human and T cells was found in the SP of R mice. Interestingly, the percentage of B cells was higher in the LN and SP of non-R mice. In contrast, in the tumor, an increased number of human cells (mostly T cells) was found in R mice. Notably, CD8+ T cells were significantly higher among TILs. A linear regression analysis was performed, and the number of human and T (CD4+ and CD8+) cells in the tumor significantly decreased (P<.001for all of them) with an increasing tumor SGR.Table: 1904P
Periphery % cells | Tumor nº cells / g | ||||||||
---|---|---|---|---|---|---|---|---|---|
LN | SP | R | Non-R | P* | |||||
R | Non-R | P | R | Non-R | P | ||||
Human cells T cells CD4 CD8 B cells | 95 78 77 23 10 | 94 76 79 20 16 | .17 .40 .54 .51 .016 | 38 81 77 23 10 | 23 71 75 24 21 | .009 .017 .68 .72 .001 | 57648 47794 38094 9210 443 | 22745 18191 14852 3052 555 | .036 .052 .069 .012 .079 |
T-test on Ln-transformed values
Conclusions
Different immune responses were observed both in the periphery and in the tumor between R and non-R mice. The humanized mouse model appears to be a valid model to evaluate immunotherapy combinations for MSS CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Colorado, Anschutz Medical Campus.
Funding
University of Colorado, Anschutz Medical Campus.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4900 - Molecular profiling and prognostic significance of TP53 mutations in Diffuse Large B Cell Lymphoma: identifying a high-risk subgroup
Presenter: Yuan-Kai Shi
Session: Poster Display session 3
Resources:
Abstract
3809 - Differential expression of various miRNAs in Pediatric Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Presenter: Vikas Gaur
Session: Poster Display session 3
Resources:
Abstract
4750 - Circulating tumour cells in head and neck and non-small cell lung cancer
Presenter: Kenneth O'Byrne
Session: Poster Display session 3
Resources:
Abstract
3704 - OX40/OX40L protein expression in Non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Presenter: Xiaoshen Zhang
Session: Poster Display session 3
Resources:
Abstract
2235 - Effect of Serum Survivin on Survival among Non-Small Cell Lung Cancer Patients; NCI Experience
Presenter: Reham Rashed
Session: Poster Display session 3
Resources:
Abstract
2788 - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning.
Presenter: Helene Vanacker
Session: Poster Display session 3
Resources:
Abstract
4689 - Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer After Adjuvant Chemotherapy
Presenter: Samuel Jacobs
Session: Poster Display session 3
Resources:
Abstract
1454 - Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites
Presenter: Hye Sook Han
Session: Poster Display session 3
Resources:
Abstract
5574 - Results from TRIO030, a Pre-Surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide
Presenter: Hsiao-Wang Chen
Session: Poster Display session 3
Resources:
Abstract
1787 - JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer
Presenter: Yasushi Sato
Session: Poster Display session 3
Resources:
Abstract